NICE does not recommend Krystexxa (Savient Pharma) for treatment of severe Gout
The National Institute for Health and Clinical Excellence (NICE) has opened a consultation on the use of Krystexxa (peglioticase) from Savient Pharma, in treating severe debilitating chronic tophaceous Gout in adults. Draft guidance does not recommend the drug for this use. NICE's independent appraisal committee has decided that the drug effectively lowers the level of uric acid in the blood for a significant proportion of patients with severe gout but the panel also noted the risk of severe adverse reactions, and concluded that there was considerably uncertainty about the drug�s long-term efficacy and safety.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.